Domestic well-known solid preparation equipment supplier: the company's main business is the research and development, production, sales and technical services of solid preparation equipment in the field of pharmaceutical equipment. 2013 the company realized operating income of 154 million yuan, and net profit of 34.72 million yuan, 2011-2013 company revenue and net profit CARG is 5.6%/1.6% respectively. The company's equipments and processes are not only applied in the pharmaceutical field, but also widely used in health care products, food and other large health industries. The company is located in the "solid preparation equipment supplier", plowing the domestic pharmaceutical equipment market, and actively expanding overseas markets, and strive to become an international mainstream solid preparation equipment suppliers, and continue to promote the strategic layout of the health industry.
The demand for solid dosage equipment is growing fast: China has become one of the fastest growing regions in the world in terms of drug consumption, and is expected to become the world's second-largest drug market after the U.S. by 2020. Continued growth of the domestic pharmaceutical industry will lead to the formation of new pharmaceutical enterprises, reform and expansion needs, coupled with the solid preparations in all pharmaceutical dosage forms in the proportion of enhancement of the pharmaceutical industry will produce multiple demand for solid preparations equipment. At present, the pharmaceutical equipment industry market concentration is low, the future will show a high-end, centralized trend, which will provide market opportunities for the company's industrial integration.
Complete product system, rich customer resources, strong R & D strength: the company is one of the few domestic enterprises that can provide a variety of mainstream granulation process equipment. With a system of solid dosage production equipment products, various categories have formed a series of products, complete specifications, optional process path is rich. At present, the company's products and services have covered more than 30 countries and regions, more than 600 international and domestic well-known pharmaceutical companies, more than 20 well-known health care products and food companies, sales network throughout the world, overseas business revenue accounted for an increase in the proportion of year by year, in 2013 has reached 18.5%. The company is a national high-tech enterprise, has set up a postdoctoral research station, is a member of the National Pharmaceutical Equipment Standardization Technical Committee, and is independently responsible for drafting six industry standards. The company has been authorized 71 patents, including 11 patents of invention, and is in a dominant position in the field of solid preparation granulation equipment manufacturing in China.